{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:12:52Z","timestamp":1783566772879,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GLOVACC"},{"name":"Japan AMED"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although therapeutic human papillomavirus vaccines could offer a noninvasive treatment for patients with cervical intraepithelial neoplasia, none has been clinically implemented. Oral administration of the therapeutic human papillomavirus vaccine IGMKK16E7 results in the histological regression of human papillomavirus 16\u2013positive cervical intraepithelial neoplasia 2\/3 to normal (complete response). We investigated biomarkers that could predict complete response after oral administration of IGMKK16E7.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Forty-two patients administered high-dose oral IGMKK16E7 in a phase I\/II trial were included. Cervix-exfoliated cells were collected before vaccine administration. Gene expression of CD4, CD8, FOXP3, programmed cell death 1 protein, CTLA4, CD103, CD28, CD80, CD86, and programmed cell death 1 ligand 1 in the cells was measured by quantitative reverse transcriptase\u2013polymerase chain reaction. Receiver operating characteristic curve analysis and Mann-Whitney tests were used to explore potential biomarkers. Pearson correlation coefficient analysis was used to correlate gene expression profiles with clinical outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The only predictive biomarker of vaccine response for which receiver operating characteristic curve analysis showed significant diagnostic performance with histological complete response was CD86 (area under the curve\u2009=\u20090.71, 95% confidence interval\u2009=\u20090.53 to 0.88, P\u2009=\u2009.020). Patients with complete response had significantly lower CD86 expression (CD86-low) than patients with no complete response (P\u2009=\u2009.035). The complete response rates for CD86-low and CD86-high\u00a0patients were 50% and 19%, respectively, and CD86-low patients had a significantly higher complete response rate (P\u2009=\u2009.047). Compared with all patients, the CD86-low group had a 1.5-fold increase in the complete response rate. Gene expression of CD86 and CTLA4 showed the strongest positive correlation with clinical outcomes in the incomplete response group (P\u2009&amp;lt;\u2009.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Low expression of CD86 in exfoliated cervical cells can be used as a pretreatment biomarker to predict histological complete response after IGMKK16E7 administration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkae091","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:37:34Z","timestamp":1726846654000},"source":"Crossref","is-referenced-by-count":1,"title":["Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis"],"prefix":"10.1093","volume":"8","author":[{"given":"Hanano","family":"Ando","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Functional Morphology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yahata","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyomi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba , Ibaraki,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba , Ibaraki,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University , Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Hori-Hirose","sequence":"additional","affiliation":[{"name":"Department of Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Data Science, Center for Clinical Science, National Center for Global Health and Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Nakayama-Hosoya","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanoko","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Taguchi","sequence":"additional","affiliation":[{"name":"World Premier International Immunology Frontier Research Center, Laboratory of Human Single Cell Immunology , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-8326","authenticated-orcid":false,"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizunobu","family":"Igimi","sequence":"additional","affiliation":[{"name":"Department of Applied Biology and Chemistry, Tokyo University of Agriculture , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kawana-Tachikawa","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny J","family":"Schust","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Duke University , Durham, NC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1919-8830","authenticated-orcid":false,"given":"Kei","family":"Kawana","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nihon University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"issue":"14","key":"2024110112135733000_pkae091-B1","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2024110112135733000_pkae091-B2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world effectiveness of human papillomavirus vaccination against cervical cancer","volume":"113","author":"Kjaer","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2024110112135733000_pkae091-B3","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Health"},{"issue":"10224","key":"2024110112135733000_pkae091-B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"2024110112135733000_pkae091-B5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"41","key":"2024110112135733000_pkae091-B6","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1016\/j.vaccine.2022.08.020","article-title":"Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021\u2014March 2022","volume":"40","author":"Prudden","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"2024110112135733000_pkae091-B7","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040428","article-title":"Therapeutic vaccines for HPV associated cervical malignancies: a systematic review","volume":"12","author":"Alouini","year":"2024","journal-title":"Vaccines,"},{"issue":"3","key":"2024110112135733000_pkae091-B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030672","article-title":"Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2\/3) associated with human papillomavirus: a systematic review","volume":"16","author":"Gon\u00e7alves","year":"2024","journal-title":"Cancers,"},{"issue":"11","key":"2024110112135733000_pkae091-B9","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1080\/21645515.2016.1199302","article-title":"Moving forward with human papillomavirus immunotherapies","volume":"12","author":"\u00c7uburu","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2024110112135733000_pkae091-B10","year":"2023"},{"issue":"2","key":"2024110112135733000_pkae091-B11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-17-2335","article-title":"Clinical and immunologic biomarkers for histologic regression of high-grade cervical dysplasia and clearance of HPV16 and HPV18 after immunotherapy","volume":"24","author":"Morrow","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10008","key":"2024110112135733000_pkae091-B12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"2024110112135733000_pkae091-B13","doi-asserted-by":"publisher","first-page":"pkad101","DOI":"10.1093\/jncics\/pkad101","article-title":"Phase I\/II randomized clinical trial of an oral therapeutic vaccine targeting HPV for treatment of CIN2\/3","author":"Kawana","year":"2023","journal-title":"JNCI Cancer Spectr"},{"issue":"24","key":"2024110112135733000_pkae091-B14","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1016\/j.vaccine.2018.05.009","article-title":"Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFN\u03b3-producing cells","volume":"36","author":"Komatsu","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"2024110112135733000_pkae091-B15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jjco\/hyz095","article-title":"Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized placebo-controlled clinical trial (MILACLE study","volume":"49","author":"Ikeda","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"2024110112135733000_pkae091-B16","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.31557\/APJCP.2021.22.7.2069","article-title":"Effect of primary systemic therapy on PD-1, PD-L1, and PD-L2 mRNA expression in advanced breast cancer","volume":"22","author":"Karsono","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"2024110112135733000_pkae091-B17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/aje\/kwj063","article-title":"The Inconsistency of \u201coptimal\u201d cutpoints obtained using two criteria based on the receiver operating characteristic curve","volume":"163","author":"Perkins","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2024110112135733000_pkae091-B18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev. Immunol"},{"issue":"9","key":"2024110112135733000_pkae091-B19","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.4049\/jimmunol.164.9.4689","article-title":"Characterization of human inducible costimulator ligand expression and function","volume":"164","author":"Aicher","year":"2000","journal-title":"J Immunol"},{"issue":"9","key":"2024110112135733000_pkae091-B20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat Immunol"},{"issue":"1","key":"2024110112135733000_pkae091-B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"2024110112135733000_pkae091-B22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/imm.12101","article-title":"Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia","volume":"139","author":"Yang","year":"2013","journal-title":"Immunology"},{"issue":"1","key":"2024110112135733000_pkae091-B23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2013.07.023","article-title":"Differential DNA methylation patterns in the CD86 gene controls its constitutive expression in keratinocytes","volume":"438","author":"Romero-Tlalolini","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2024110112135733000_pkae091-B24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1525-1438.2007.00904.x","article-title":"Expression of the costimulatory molecule CD86, but not CD80, in keratinocytes of normal cervical epithelium and human papillomavirus-16 positive low squamous intraepithelial lesions","volume":"17","author":"Ortiz-S\u00e1nchez","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"2024110112135733000_pkae091-B25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059eCollection2018","article-title":"Dendritic cells and CD8 T cell immunity in tumor microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"2024110112135733000_pkae091-B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/vaccines4040037","article-title":"Is there still room for cancer vaccines at the era of checkpoint inhibitors","volume":"4","author":"Karaki","year":"2016","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"2024110112135733000_pkae091-B27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: Interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkae091\/59212738\/pkae091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/6\/pkae091\/60290068\/pkae091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/6\/pkae091\/60290068\/pkae091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:14:32Z","timestamp":1730463272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkae091\/7762640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkae091","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,20]]},"article-number":"pkae091"}}